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Background: researchers and sponsors increasingly confront the issue of whether participants in a clinical trial
should have post-trial access (PTA) to the trial drug. Legislation and guidelines are inconsistent, ambiguous or
silent about many aspects of PTA. Recent research highlights the potential importance of systematic reviews
(SRs) of reason-based literatures in informing decision-making in medicine, medical research and health policy.
Purpose: to systematically review reasons why drug trial participants should, or need not be ensured PTA to the
trial drug and the uses of such reasons. Data sources: databases in science/medicine, law and ethics, thesis
databases, bibliographies, research ethics books and included publications’ notes/bibliographies. Publication
selection: a publication was included if it included a reason as above. See article for detailed inclusion conditions.
Data extraction and analysis: two reviewers extracted and analyzed data on publications and reasons. Results: of
2060 publications identiﬁed, 75 were included. These mentioned reasons based on morality, legality, interests/
incentives, or practicality, comprising 36 broad (235 narrow) types of reason. None of the included publications,
which included informal reviews and reports by ofﬁcial bodies, mentioned more than 22 broad (59 narrow)
types. For many reasons, publications differed about the reason’s interpretation, implications and/or persua-
siveness. Publications differed also regarding costs, feasibility and legality of PTA. Limitations: reason types could
be applied differently. The quality of reasons was not measured. Conclusion: this review captured a greater
variety of reasons and of their uses than any included publication. Decisions based on informal reviews or
sub-sets of literature are likely to be biased. Research is needed on PTA ethics, costs, feasibility and legality
and on assessing the quality of reason-based literature.
Introduction
Special arrangements to ensure that research partici-
pants have post-trial access (PTA) to the trial drug can
be crucial for participants worldwide who help test
drugs unavailable through government-funded services
(Kolata and Eichenwald, 1999; National Bioethics
Advisory Commission Group, 2001; Macklin, 2004;
BBC staff, 2007). With the increasing globalization of
research,sponsorsandresearchersincreasingly confront
the issue of whether drug trial participants and/or their
communities should, or need not be ensured PTA to the
trial drugorother possible beneﬁts. Aspectrum of views
has been expressed by academics, participants, oversight
agenciesandindustryorganizationsonthisissue(Busse,
1997; National Bioethics Advisory Commission Group,
2001; PhRMA Group, 2001; Nufﬁeld Council on
Bioethics Group, 2002; Berkley, 2003; Fernandez et al.,
2003; Greenwood and Hausdorff, 2003; Macklin, 2004;
Slack et al., 2005; Shaffer et al., 2006; Lavery, 2008;
Sofaer et al., 2009). International and national guide-
lines require PTA to the trial drug in at least some
circumstances (CIOMS, 2002; The European Group
on Ethics in Science and New Technologies to the
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Research, 2006; World Medical Association, 2008) and
impose various procedural obligations, such as inclu-
sion of information about PTA in literature for partici-
pants and in registries (UNAIDS Group, 2000; National
Bioethics Advisory Commission Group, 2001; CIOMS,
2002; Nufﬁeld Council on Bioethics Group, 2002;
World Medical Association, 2004; World Medical
Association, 2008); a recent literature assesses compli-
ance. (Cohen et al., 2008; Ciaranello et al., 2009; Shah
et al., 2009). However, the guidelines conﬂict, change
their stance on PTA (World Medical Association,
2004; Wolinsky, 2006; World Medical Association,
2008), and give little detail about when PTA to trial
drugs should be ensured, for how long, and by whom.
The US Code of Federal Regulations does not mention
PTA (45CFR46, revised 2009). Some major sponsors
of research are prohibited from funding PTA (NIH
Group, 2005) or state that their remit excludes this
(Wellcome Trust Group, 2004).
A systematic review involves an (as far as possible)
exhaustive and reproducible search and evaluation of
literature that meets pre-speciﬁed inclusion criteria to
answer a focused question. The genre was developed in
the late 1970s in social science, and later spread to medi-
cine, where it was used with the aim of enabling max-
imally informed, minimally biased decisions. It was
transferred, with similar intent, to non-clinical empir-
ical research, including empirical bioethics (which uses
qualitative or quantitative research to address empirical
questions relevant to bioethics), and philosophical
or reason-based bioethics (which employs reasoning
to address bioethical questions) (Lemmer et al., 1999;
McCullough et al., 2007; Strech et al., 2008). While sys-
tematic reviews of the ‘vast literature [on research
ethics]’ (Emanuel et al., 2008: 4) have been advocated
to help clinical researchers grasp its current status, and
to improve decision-making in health care, there is only
one systematic review of philosophical bioethics
(McCullough et al., 2007). It covers just seven articles
and addresses an ethical question: the question of
whether a speciﬁc clinical intervention is ethically justi-
ﬁed. As we explain and argue elsewhere, systematic re-
views that answer an ethical question are likely to
mislead decision-makers, and more sweeping revisions
of systematic review methodology than McCullough
et al. propose are needed for systematic reviews of
reason-based literature to be of use. In particular, a
systematic review of philosophical bioethics should ad-
dress the factual question of which reasons have been
givenwhendiscussingtheethicalquestion,anditshould
present detailed information on reasons. As we also
argue, decision-makers will still need literature that dis-
cusses the quality of reasons and their implications for
the ethical question: a systematic review of reasons and
literature assessing quality are each necessary parts
of decision-makers’ dossier (Sofaer and Strech).
This systematic review addresses the question: ‘which
reasons have been given for the views that former par-
ticipants in a drug trial should, or need not, be ensured
PTA to the trial drug?’ (Ensuring PTA here implies spe-
cial arrangements when participants will otherwise lack
PTA, but implies no verbal or written assurances to po-
tential participants or participants.) A secondary ques-
tion is: ‘how have these reasons been used to argue that
post-trial access should, or need not, be ensured?’ In
particular, what were the reasons taken to imply?
Were the reasons endorsed? Were uses of reasons in-
formed by previously published uses of the same
reason? It is the ﬁrst systematic review of reasons, and
ﬁrst systematic review of a large philosophical bioethics
literature. This systematic review does not settle the
question of whether former participants should, or
need not be ensured PTA to the trial drug. However,
as explained later and elsewhere, its usefulness to
decision-makers and philosophers lies in aiding the
identiﬁcation of the strong reasons and their implica-
tions for ensuring PTA, and in setting the agenda for
empirical and conceptual research to improve the
information-base of decision-making (Sofaer and
Strech, 2011).
Methods
We included a publication, e.g. article, if and only if:
(I) It included a reason why PTA should or need not
be provided.
(II) The PTA was for former participants in a drug
trial.
(III) The PTA was to a drug tested in the trial; and
(IV) The publication was a peer-reviewed, published
academicarticleorbook;national-level reportor
working paper; or PhD thesis.
Reason in condition (I) covers reasons that support
ensuring (PTA to the drug or other possible beneﬁt),
and reasons that were simply mentioned without
being explicitly endorsed or rejected. PTA provision
mentioned under condition (I) includes PTA-
promoting actions e.g. the funding or affordable pricing
of the drug post-trial, pre-trial planning about PTA
and requiring such actions. We employed conditions
(II) and (III) because of possible differences between
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non-participants, and for providing the trial drug
versus e.g. trial devices (Millum, 2009). Condition
(IV) excluded laws, legal cases, case commentaries and
guidelines because of the literature’s extent and the dif-
ﬁculty of describing a reproducible search. Publications
were not excluded explicitly based on language: we are
together able to read in a number of languages and
planned to employ translators if the search yielded pro-
mising publications that we could not adequately
understand.
Reference librarians helped to select databases in sci-
ence/medicine (Medline, LocatorPlus), law (Westlaw
International) and ethics (ETHXWeb, JSTOR,
Euroethics, Endebit), as well as thesis databases
(Ethos-Beta Electronic Theses Online Service,
WorldCat Dissertations; the latter is not limited to
PhD theses). No database’s index terms included
post-trial access or synonym. For each database, we
ﬁrst searched with Boolean operations of keywords
and of the database’s relevant index terms, if any. On
retrieving publications known to meet the inclusion
conditions, we identiﬁed their index terms and key-
words (including but not limited to ones referring to
PTA), and sorted these into ﬁve content classes: access,
clinical trials, drugs, ethics and research subjects. For
our database-speciﬁc search terms and strings, please
see table A1. Searches had no start-date but, where spe-
ciﬁable, a 2 October 2009 end-date. We next used bib-
liographic review and recommendations from authors
of included publications to identify reports and books
on research ethics, and hand-searched their tables of
contents and indexes. Last, we searched in-text refer-
ences, notes and bibliographies of included publications
for promising titles (a ‘snow-ball search’) (Greenhalgh
and Peacock, 2005).
Next, we worked independently through the resulting
publication list to exclude publications based on their
title, any abstract/extract and any index terms. Each
author thus produced a list of publications that were
candidates for meeting the inclusion conditions. One
list had 134 publications, the other had 95; 93 were on
both lists. After jointly resolving discrepancies to create
one list of 121 publications, we each read the full text of
each and selected those that met the above inclusion
criteria. We repeated the process on the results of the
snow-ball search until no further qualifying publica-
tions emerged. Figure 1 documents the search.
We distinguish here between the mention of a reason
expressed by a speciﬁc passage in a publication (Reason
Mention) from a Type of Reason, which may have differ-
ent Reason Mentions in different publications. We
distinguish also between broad Types of Reason, e.g.
avoid exploitation, and narrow Types of Reason, e.g.
avoid exploiting research participants,o ravoid ex-
ploiting the host country. In our analysis, each broad
Type of Reason comprises several narrow types, and
each narrow type falls under one broad type. Bold text
indicates Types of Reason.
As we found no useful precedent for the systematic
extraction and analysis of Reason Mentions, we de-
veloped a framework of narrow and broad Types of
Reasons that best accommodated the reasons men-
tioned in the included publications. (For the develop-
ment, details and limitations of our model for
systematic reviews, see (Strech and Sofaer, How to
write a systematic review of reasons, manuscript.) In
brief, one author (NS) commenced extraction by iden-
tifyingandnumbering10publicationsalreadyknownto
meet the inclusion conditions, and which illustrated
a range of reasons and challenges to analysis. Both au-
thors then independently extracted Reason Mentions
from publication 1 and assigned each Reason Mention
to a broad and a narrow type, assigning Reason
Mentions todifferent narrow TypesofReasonwhenever
itwassuspectedthattheReasonMentionsmightexpress
different Types of Reason. (The narrow Types of Reason
were thus very narrow.) Discrepancies between the re-
sulting spreadsheets were identiﬁed, discussed and
resolved. The process was repeated, for a total of nine
publications, until coding additional publications re-
sulted in no further changes to data types, and discre-
pancies between corresponding cells’ contents were
easily resolvable. N.S. then extracted and analyzed data
from the remaining publications. D.S. checked the ana-
lysis. N.S. then identiﬁed and removed repeated Reason
Mentions within each publication.
Last, N.S. used Excel to derive/calculate the results,
which D.S. checked. We also conducted a sensitivity
analysis, which aimed to see whether the difference in
the number and variety of reasons captured by our sys-
tematic review versus the most comprehensive included
publication was preserved when Types of Reason were
more broadly individuated: we merged similar narrow
Types of Reason, and recounted the numbers of reasons
identiﬁed by our systematic review versus the most
comprehensive publication. Table 1 shows which
Types of Reason were merged (see the last note under
the table).
Disagreements and problems that arose in the selec-
tion of publications and the data extraction and analysis
were resolved by frequent discussion and not by defer-
encetothesecondauthor;wedidnotneedtoappealtoa
third person. Details of the types of data extracted and
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Results
Publication Characteristics
Seventy-ﬁve publications were included
(Supplementary Figure 1), published between 1991
and September 2009 inclusive. Nearly three-quarters
(55, 73%) were published between 2002 and
September 2009 inclusive. There was no book focusing
on PTA. Publications used many different terms to refer
to PTA.
1 Table 2 describes further characteristics of the
included publications.
Identity, Incidence and Implications of Reasons
The 75 publications together included 781 Reason
Mentions, which we grouped under 36 broad and 235
narrow Types of Reason; when similar narrow types
were merged to conduct the sensitivity analysis, there
were 202 narrow Types of Reason (Table 1). To gener-
alizeoverthebroadTypesofReason,reasonswerebased
on considerations of morality, legality, interests and in-
centives, and/or practicality. Moral reasons belonged to
twooverlappingfamilies:basedonjustice,ortherolesof
and relationships between stake-holders in research.
Reasons classed under legality included reasons claim-
ing that guidelines do (or do not) require ensuring PTA.
The most frequently mentioned broad Types of
Reason were avoid exploitation (which had 97 Reason
Mentions) and stake-holder interests: the interests of
stake-holders in research such as participants, sponsors,
governments of countries hosting research and society
(86 Reason Mentions). A total of 14 (39%) broad Types
of Reason had 5 or fewer Reason Mentions. The
most-mentioned narrow Types of Reason were avoid
exploiting the host country (23 Reason Mentions;
mentioned only for ensuring PTA), and if PTA is
required, this will reduce the incentive to conduct re-
search with consequent loss of potential beneﬁts to
potential research hosts (23 Reason Mentions; men-
tioned only for the view that PTA need not be ensured),
Figure 1. Selection of publications. ML, Medline; WL, Westlaw; ETHX, ETHXWeb; JST, JSTOR; E-B, Ethos-Beta Electronic Theses
Online Service; WC, Worldcat; Euroeth., Euroethics; LocPl., LocatorPlus; asterisks indicate number of publications that were not
also retrieved by the systematic search in ML. Reasons for excluding 1985 publications: no content on research conducted on
humans; or no content on clinical trials of drugs conducted on humans; or no content on whether PTA the trial drug should; or
need not, be ensured to participants, their host community or country; or no reason for the view that PTA the trial drug should
(or need not) be ensured to participants.
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1.1: MORAL REASONS BASED ON JUSTICE
Avoid exploitation [97]
Avoid exploiting the host country [23] (1)
Avoid exploiting the host community [18] (1)
Avoid exploiting participants [19]
If avoiding exploitation requires PTA to be provided, then prior agreements should be required [8]
Research provides beneﬁts other than PTA to the trial drug [6]
Fair level of beneﬁts may but need not include PTA [9]
Requiring PTA may not sufﬁce for providing fair level of beneﬁts when the costs of participating in
research are high or the beneﬁts to the sponsor are great [3] (2)
Requiring PTA may not sufﬁce for providing fair level of beneﬁts because many trials do not yield a safe
and effective intervention immediately or ever [1] (2)
Requiring PTA may not sufﬁce for providing fair level of beneﬁts when trial intervention is unsuccessful
and no other beneﬁts are provided [1] (2)
Avoid exploiting people (of unspeciﬁed identity) [13 for ensuring PTA, 2 for the view that PTA need
not be ensured]
Rights [2]
Right to health care [1]
Participants’ right that the terms of the research should be justiﬁable to them [1 unclear implication]
Autonomy [38]
A resource-poor community cannot give valid consent to hosting research unless there is a realistic plan
to give it PTA [3]
The participant’s consent is insufﬁciently informed because the participant was unable to predict what it
will be like to lack PTA [1] (11)
The participant’s consent is insufﬁciently informed because the consent form lacked an accurate account
of PTA [2] (11)
The participant’s consent is insufﬁciently informed because the participant has therapeutic misconceptions
[2] (11)
The participant’s consent is insufﬁciently informed because investigators failed to ensure that the
participant understood all relevant information [1] (11)
The participant gave informed consent to participating in research that would not give PTA [12]
To enrol in a trial is to assume the risk, and thus responsibility, of lacking PTA [2]
The stake-holders in the research agreed before the trial that there would be no PTA [2]
Host community fairly selected a package of beneﬁts that excludes PTA [1]
The autonomy of the entity that hosts the research is paternalistically restricted when others choose
which research-related beneﬁts it will receive [9]
Offering PTA to potential participants may create or exacerbate therapeutic misconceptions [2]
Reciprocity [38]
Unspeciﬁed reciprocity [9] (12)
Reciprocity in return for assuming risk [6] (12)
Reciprocity to participants from researchers [5] (13)
Reciprocity to participants from society [5]
Reciprocity to participants from the sponsors [4] (13)
Reciprocity to participants from host country non-participants [3]
Reciprocity to the host community from researchers [1] (14)
Reciprocity to the host community from the sponsor [1] (14)
(continued)
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Reciprocity to the host community from the world [2]
Reciprocity to participants from non-participants in the host country who have the same medical
condition as participants [1]
Giving PTA to the successful intervention to former participants doubly disadvantages participants in
unsuccessful trials, who received fewer beneﬁts during the trial [1]
Distributive justice [23]
Unspeciﬁed distributive justice [1]
Equal access to healthcare for inhabitants of host and sponsor countries [1]
Inequalities between resource-rich sponsor and resource-poor host countries [3]
Providing PTA reduces ﬁnancial inequalities between U.S. researchers and participants in resource-poor
countries [1]
Prior agreements to provide PTA reduce inequalities in PTA between resource-rich and -poor
countries [1]
If PTA is not guaranteed, there will be inequalities in PTA for participants who have, and participants
who lack, health insurance [1]
Fair division of beneﬁts and burdens of research between countries that host, and countries that
sponsor, the research [4]
Fair selection of individuals to participate in research implies that if resource-poor country individuals
will not beneﬁt from the research, they should not participate [2]
If researchers and sponsors do not provide PTA, they risk failing to ensure that participants receive
morally obligatory healthcare [1]
If beneﬁts to the host community are negotiated between stake-holders in research, host communities
will not receive fair beneﬁts because their bargaining position is relatively weak [2] (18)
If beneﬁts to the host community are negotiated between stake-holders in research, different host
communities will receive different beneﬁts [1] (18)
If PTA is required, the sponsoring government will bear an unjustly large proportion of the cost [1]
Providing PTA to former participants increases inequalities between participants and those who did not,
or could not, participate [2]
Different standards [23]
Avoid using double standards for research conducted in different places [1]
Resource-poor country participants should receive the same post-trial beneﬁts as resource-rich country
participants [1]
Researchers should be held to a higher standard than physicians and business persons [1]
Pre-trial agreements are not generally used, so they should not be required [4]
PTA is not required to conduct research in resource-rich countries, so it should not be required to
conduct research in resource-poor countries [2]
Pre-trial plans are not required to conduct research in resource-rich countries, so they should not be
required to conduct research in resource-poor countries [2]
Pre-trial agreements are not required to conduct research in resource-rich countries, so they should
not be required to conduct research in resource-poor countries [7]
International guidelines do not require PTA [4]
Clinical research should not be held to a higher standard than other international enterprises [1]
Physical health [22]
Participants’ health need [16]
Host community’s health need [2]
Urgent need to reduce huge burden of disease justiﬁes pressing on with research without PTA [2]
(continued)
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Promising [13]
PTA was promised [1]
PTA was not promised [1]
Promise to provide PTA may be broken [11]
Psychological health [10]
Lack of PTA may cause psychological harm to former participants [10]
Non-maleﬁcence [16]
Minimize possible harms [1]
Participants should not have worse health after the trial than during [10]
Participants should not have worse health care after the trial than during [1]
Participants should not have worse health after the trial than before [2]
Participants should not have worse health after the trial than if they had not participated [1]
Non-maleﬁcence requires only that researchers and sponsors do not withhold any normally available
effective treatment [1]
Beneﬁcence [9]
Unspeciﬁed beneﬁcence [1]
Participants must beneﬁt from the research [4]
Participants should continue receiving treatment for as long as they beneﬁt from it [2]
Beneﬁcence requires only that researchers and sponsors do not withhold any normally available
effective treatment [1]
Reward and recognition [9]
Reward for research participation [5]
Recognition of participants’ contribution [3]
Pharmaceutical companies should show respect for participants [1]
Compensatory justice [7]
Compensation for research-related harm [5]
Compensation for historic injustice [2]
Avoid objectiﬁcation [5]
Avoid objectifying the host community [1]
Avoid objectifying participants [3 for ensuring PTA, 1 for the view that PTA need not be ensured]
Avoid abandonment [3]
Avoid abandoning participants [3]
Fairness [5]
It is unfair to require sponsor to provide PTA when participation is low risk and beneﬁts to sponsor are
small [1]
Unspeciﬁed fairness [3 for ensuring PTA, 1 for the view that PTA need not be ensured]
Responsiveness [4]
Responsiveness to host countries’ needs [4]
Access [4]
Former participants lack alternative access to care [4]
Other justice [5]
Unspeciﬁed justice [4]
Priority to the sickest [1]
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Charity [2]
Be charitable to former participants [2]
1.2: MORAL REASONS BASED ON ROLE AND RELATIONSHIP
Role [30]
Role of researchers
Researchers have a professional “commitment” to participants [1] (3)
Researchers bear a duty of care to participants [2] (3)
Researchers have moral ﬁduciary obligations to participants [1] (3)
Researchers are obliged not to disregard participants’ well-being [1] (3)
Researchers are responsible for former participants’ welfare [1] (3)
Because resource-rich countries have shirked their obligation to alleviate poverty in resource-poor
countries, the role of researchers from resource-rich countries includes provision of fair beneﬁts [1]
Researchers are not responsible for providing healthcare [5]
Researchers are not responsible for allocating resources between research and treatment [2]
Researchers’ and sponsors’ primary role is not to develop resource-poor countries [1]
Researchers are not responsible for funding development [1]
Researchers are obliged to be honest, but lack more substantial obligations to provide PTA [1]
Researchers’ primary role is to conduct research [1]
Researchers’ role is distinct from physicians’ role [1]
Role of government
Governments’ role includes deciding how to allocate resources between research and treatment [1]
Governments’ role includes providing health care [5]
Role of sponsor
Sponsor is not responsible for providing healthcare [2]
Sponsor is responsible for allocating resources between research and treatment [1]
Sponsors’ role is not to reduce inequalities between resource-rich and -poor countries [1]
Relationship [7]
Relationship between researchers and host community [1]
Participants entrust aspects of their health to researchers [3] (19)
Unspeciﬁed relationship between researchers and participants [2 for ensuring PTA, 1 for view that
PTA need not be ensured] (19)
Concept of participant [4]
Subjects are victims [1]
Subjects are altruistic heroes [1]
Subjects are opportunists [1]
Subjects are willing contractors [1]
1.3: INTERESTS AND INCENTIVES
Stake-holders’ interests [86]
Participants’ interests
Participants’ interests: PTA to trial drug in participants’ interests [1]
Participants’ interests: treatment only during trial is better than no trial and no treatment [8]
Participants’ interests: even if trial will not provide PTA, participation buys time for future
break-throughs [1]
(continued)
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Participants’ interests: participants not harmed by trial [1]
Individual participant’s interests: trial drug not indicated for former participant post-trial [6]
Participants’ interests: PTA to trial drug may harm former participant [2]
Providing PTA to former participants increases inequalities between participants and those who
did not, or could not, participate, and thus has the potential to increase tensions within host
community [2]
Extent of sponsor’s ﬁnancial obligations depends on priorities of participants and host countries
[1 unclear implication]
Host country’s and community’s interests
Host country’s interests (unspeciﬁed) [1]
Host community’s interests: research is unlikely to improve host community’s health unless there is
prior commitment to PTA [1]
Host countries do not lose beneﬁts if research that would not beneﬁt them is prevented [1]
PTA to trial intervention is one of several possible beneﬁts to the community [1]
Host country’s interests: country beneﬁts from research even if it doesn’t receive PTA [1]
Host community’s interests may be better served by receiving beneﬁt other than PTA [13]
Host country’s interests: trial will not provide PTA but is necessary to provide access in the
long-term [3]
Loss of potential beneﬁts to host countries: even if there is no PTA immediately after the trial, price
of intervention developed will eventually drop to the point that the host country can afford it [4]
Sponsor country’s and society’s interest
Sponsor country’s interests: preventing the spread of infectious disease from resource-poor
countries [1]
Society’s interests: promote research [2]
Society’s interests: better that product is developed to enable some people to have access than not to
develop it [2]
Society’s interests: trial without PTA will advance knowledge and thereby beneﬁt society [1]
Society’s interests: withhold successful drug from host community to prevent emergence of
drug-resistant disease [3]
Sponsor’s and share-holders’ interests
Sponsor’s interests: providing PTA enables collection of data that lengthens product’s market-life [1]
Sponsors’ interests: providing PTA improves drug company’s public image [1]
If the sponsor does not provide PTA, it is possible that the research will be regarded as unethical, in
which case the sponsor will not be able to obtain marketing approval for the product developed,
with consequent loss of potential beneﬁts to society [1]
If PTA is not guaranteed, activists may prevent pharmaceutical companies from recruiting further
participants [1]
When pharmaceutical company funds PTA, this reduces share-holders’ proﬁts [1]
Researchers’ interests
Researchers’ interests: burden to researchers of providing PTA is too great [1]
Incentive [66]
Offer of PTA gives individuals an incentive to participate [2]
Offer of PTA gives communities an incentive to host research [1]
Giving PTA to the host population reduces the chance that individuals will be unduly induced to
participate [1]
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Requiring PTA would comprise a disincentive to conduct research [16] (10)
Requiring PTA would comprise a disincentive to conduct small, exploratory studies [1] (10)
If pre-trial commitment to funding PTA is required, this will reduce the incentive to conduct research
because funders are unwilling to commit to funding PTA prior to receiving research results and
consequent public pressure to provide PTA [1]
If PTA is required, this will reduce the incentive to conduct research, with consequent loss of potential
beneﬁts to potential research hosts [23]
Progress occurs in multiple steps, so requiring PTA to be provided immediately may reduce the
research conducted and thereby cause loss of potential beneﬁts to host countries [2]
If PTA is required, research will not be conducted in resource-poor contexts whose infrastructure
precludes PTA, with consequent loss of potential beneﬁts to the neediest potential research hosts [1]
Offer of PTA may unduly induce individual to participate [8]
Offer of PTA may unduly induce population to host research [1]
Trust [6]
Ensuring PTA helps maintain participants’ trust in research [1]
Ensuring PTA helps maintain potential participants’ trust in research [3]
If PTA is not provided, former participants may lose trust in research and may consequently have less
incentive to participate again [1]
Expectations [2]
Participants expect that they will have PTA [1]
Communities that host research expect that the intervention that they help to develop will be used to
improve their health [1]
1.4: PRACTICAL REASONS
Stake-holders’ competence [43]
Researchers’ competence
Researchers are able to advocate for PTA [8]
Researchers and sponsors cannot do more than advocate for PTA [1]
Researchers lack skills and experience to negotiate fair beneﬁts [1]
Researchers lack skills and experience to provide PTA [1]
Researchers lack resources to provide PTA [3]
Researchers lack funding to provide PTA [1]
Researchers lack (unspeciﬁed) power to ensure PTA [2]
Researchers lack power to ensure PTA because lack power over drug funding by foreign aid [1] (4)
Researchers lack power to ensure PTA because lack power over drug funding by host countries [1] (4)
Researchers are unable to inﬂuence host country’s health policy [1]
Researchers lack power over health policy [3] (4)
Researchers lack power over host country’s health policy [1]
Researchers and sponsors lack power to ensure PTA because PTA depends on many factors their
beyond control [1]
Researchers lack power over drug approval in host countries [1] (4)
Researchers lack power to ensure PTA because they lack power to approve drugs [1] (4)
Sponsor’s competence
Sponsor lacks resources to deliver PTA [2]
Sponsors lack power to make unilateral decisions about PTA [3] (5)
Sponsors have limited power over priorities of agencies providing health care [1] (5)
(continued)
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Sponsor lacks power to ensure PTA because lacks power over drug funding by host countries [1] (5)
Sponsor lacks power to ensure PTA because lacks power over drug funding by foreign aid [1] (5)
Sponsor lacks power to ensure PTA because lacks power to approve drugs [3] (5)
Sponsors lack legal power over drug approval process in sponsor and host countries and so cannot
guarantee reasonable availability [1] (5)
Sponsor lacks power to make unilateral decision at the start of the trial to give PTA [1 for ensuring
PTA, 2 for view that PTA need not be ensured] (5)
Logistical obstacles [46]
Lack of host country infrastructure makes PTA unlikely unless PTA is guaranteed [1] (7)
Unspeciﬁed logistical obstacles to implementing PTA [20]
Difﬁcult to locate former participants in need of treatment [4]
Lack of host country infrastructure makes it difﬁcult to provide PTA [4] (7)
Lack of host country infrastructure means that even if sponsor supplies intervention post-trial, former
participants are unlikely to beneﬁt [2] (7)
Administration of intervention post-trial must be supervised [1]
Unrealistic to expect researchers to provide PTA [4] (8)
Unrealistic to expect sponsors to provide PTA [2] (8)
Funders unwilling to guarantee to fund PTA before knowing study results [3]
Difﬁcult to co-ordinate stake-holders to provide PTA [2]
Further research may be needed after showing effectiveness and safety before drug can be provided [3]
Research funders have not funded negotiations with host regarding beneﬁts [1]
Cost [30]
Drug company sponsors proﬁt from the research [3]
Pharmaceutical company sponsors make large proﬁts from the research [1]
The sponsor’s revenue from marketing a successful drug covers the cost of providing PTA [1]
Cost of funding PTA is high [5] (15)
Cost of funding PTA to sponsor may be too high [3] (15)
Whether a trial is ethical does not depend on whether sponsor can afford to provide PTA [1]
The higher the cost of PTA, the lower the chance that PTA will be provided [2]
Cost of funding PTA to the sponsoring government may be too high [1]
The sponsor needs to recoup the cost of developing the intervention [4]
If PTA is provided, then less research can be conducted [4 unclear implications]
Extent of sponsor’s ﬁnancial obligations depend on research type [1 unclear implication]
The lower the cost of PTA, the stronger the reason to provide it [1 unclear implication]
Safety and/or effectiveness [21]
Trial drug is effective [1] (9)
Trial drug is safe and effective [1] (9)
Trial drug is ineffective [2] (6)
Trial drug is not safe and/or not effective [3] (6)
Further research may be needed to show effectiveness and/or safety [6]
Many trials do not yield a safe and effective intervention immediately or ever [1] (6)
Purpose of research [13]
The purpose of research includes providing PTA to beneﬁcial interventions [1]
The purpose of research is to develop interventions to improve the health of the population on which
the intervention was tested [3]
(continued)
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The primary purpose of research is not to further international distributive justice [1]
The purpose of research is distinct from the purpose of health care [4]
The purpose of research is not to further social justice in resource-poor countries [1]
The purpose of research is to obtain regulatory approval for the trial intervention in sponsor’s
country [1]
The purpose of research is to produce generalizable knowledge to improve health (of unspeciﬁed
individuals) [1 for ensuring PTA, 1 for the view that PTA need not be ensured]
Efﬁciency [5]
It is more efﬁcient to treat former subjects than non-participating community members [1]
Requiring PTA encourages scientists to combine studies, and thereby to reduce the number of
participants [1]
Researchers may be inefﬁcient healthcare providers [2]
Maximize the amount of research conducted and thus the potential health beneﬁts from research [1]
Science [4]
Obligation to maximize the scientiﬁc value of the trial and so to maintain the control group after the
end of the trial [4]
Context of research [3]
Resources for providing PTA are scarce [2 unclear implications]
Limited motivation of researchers and sponsors to provide PTA [1 unclear implication]
1.5: LEGAL REASONS
Legality [31]
PTA is required by guideline [8]
Researchers have legal ﬁduciary obligations to participants [2]
International guidelines do not require PTA [4]
PTA not required by US legal code [1](17)
Research funder forbids use of its funds for PTA [3]
It is illegal for researchers to provide health care outside of a clinical trial [1]
It is illegal for sponsor to provide health care outside of a clinical trial [4] (16)
It is illegal for sponsor to provide a non-approved trial intervention post-trial [1] (16)
Difﬁcult to interpret guideline or ethical principle that requires PTA [4]
Intellectual property rights may make it impossible for researchers to guarantee PTA prior to trial [2]
PTA is not required by guideline (17)
Notes:  This table lists all the mentioned reasons why PTA should or need not be ensured, including those that were rejected,
or neither rejected nor endorsed. Given that reasons will in any case need to be appraised, it better aids the decision-maker to
err on the side of comprehensiveness.  Finer-grained data is available on request.  No colour background: reason used just
for the view that PTA should be ensured; number in square brackets with no colour background is number of reason mentions
used for the view that PTA should be ensured.  Grey background: reason used just for the view that PTA need not be ensured
or with unclear implications; number in square brackets with grey colour background is number of reason mentions used for
the view that PTA need not be ensured.  Red background: some reason mentions were for the view that PTA should be
ensured and some for the view that it need not be ensured, or implications for PTA were left unspeciﬁed.  Note that, for
many broad Types of Reason, the number after the broad type (e.g. Avoid exploitation) is more than the sum of numbers after
the narrow types because, for colourless or grey reasons the number given excludes the few reason mentions with unclear
implications.  Round parentheses: reasons followed by the same number in parentheses were merged in the sensitivity analysis.
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Features of publication n (%) of publications
Content type
a
Philosophy discussion
b 62 (83)
Policy critique
c 26 (35)
Informal philosophical review
d 18 (24)
Policy review
e 18 (24)
Opinion piece
f 4 (5)
Case study of PTA
g 2 (3)
Commentary
h 2 (3)
Empirical study
i 2 (3)
Discussion of PTA legal case
j 1 (1)
Publication type
Article 55 (73)
Sections with distinct author groups in edited books 9 (12)
k
Report 5 (7)
Journal-published letters 3 (4)
Journal-published news article 1 (1)
Monograph 1 (1)
PhD thesis 1 (1)
PTA discussed in relation to which trials?
All 57 (76)
HIV/AIDS
l 18 (24)
Mental health 1 (1)
Genetics 1 (1)
Published in 2004 (the most proliﬁc year) 13 (17)
Publications whose main topic was not PTA 47 (63)
Publications concerning only research conducted by resource-rich in
resource-poor countries
58 (77)
English-language publications
m 75 (100)
Characteristics of 55 articles included
Field of journal
Medicine 18 (33)
Bioethics 17 (31)
Law 12 (22)
Public health 4 (7)
Science 2 (4)
Articles published online at www.scidev.net 2 (4)
aPublications were assigned more than one content type where appropriate.
bDiscussion of whether there are PTA obligations.
cAssessment of PTA regulations, guidelines and/or policies.
dPublication that mentioned >12 narrow types of reasons that met the inclusion conditions.
eReview of regulations, guidelines and/or policies regarding PTA.
fExpression of mere opinion about whether there are PTA obligations.
gDescription of trial in which PTA was an issue.
hCommentary on another publication included in this review.
iPublication reporting empirical study, not necessarily of PTA.
jDiscussion of legal case in which PTA was an issue.
kThe 9 sections occurred in a total of three edited books.
lThe HIV/AIDS publications concerned AZT, ART or vaccine research.
mSee ‘Limitations’ section.
172  SOFAER AND STRECHfollowed by avoid exploiting participants (19 Reason
Mentions; mentioned only for ensuring PTA), and
avoid exploiting the host community (18; mentioned
only for ensuring PTA). Most (210, 89%) narrow Types
of Reason had ﬁve or fewer Reason Mentions.
ReasonMentionsclassedunderavoidanceofexploit-
ation concerned the exploitation of the host country
(23 Reason Mentions
2 (Crouch and Arras, 1998;
Glantz et al., 1998; Benatar, 2000; Lie, 2000; Cooley,
2001; National Bioethics Advisory Commission
Group, 2001; Chang, 2002; Kottow, 2002; Orentlicher,
2002; Page, 2002; Participants in the Conference on
Ethical Aspects of Research in Developing Countries,
2002; Lo and Bayer, 2003; Lavery, 2004; Macklin,
2004; Page, 2004; Participants in the 2001 conference
on ethical aspects of research in developing countries,
2004; Emanuel, 2008; Wertheimer, 2008)), participants
(19Reason Mentions in 15publications (Cleaton-Jones,
1997; McLean, 1997; Crouch and Arras, 1998; Emanuel,
1998; National Bioethics Advisory Commission Group,
2001; Brody, 2002; Nufﬁeld Council on Bioethics
Group, 2002; Orentlicher, 2002; Macklin, 2004;
Ballantyne, 2005; Grady, 2005; Benatar and Fleischer,
2007; Hawkins and Emanuel, 2008; Lavery, 2008;
Zong, 2008)), the host community (18 Reason
Mentions in 13 publications, (Gostin, 1991; Annas and
Grodin, 1998; Glantz et al., 1998; Page, 2002;
Participants in the Conference on Ethical Aspects of
Research in Developing Countries, 2002; Macklin,
2004; Participants in the 2001 conference on ethical as-
pects of research in developing countries, 2004; Yearby,
2004; Basu et al., 2006; Gbadegesin and Wendler, 2006;
Emanuel, 2008; Lavery, 2008; Siegel, 2008)), or an un-
speciﬁed group (16 Reason Mentions in 8 publications,
(CrouchandArras,1998;Participants intheConference
on Ethical Aspects of Research in Developing Countries,
2002; Macklin, 2004; Ashcroft, 2005; Ballantyne, 2006b;
Lavery, 2008; Siegel, 2008; Sachs, 2009)). Publications
agreeing that avoiding exploitation is sometimes or
always a reason for ensuring PTA differed as to whether
avoiding exploitation requires providing PTA in par-
ticular, (McLean, 1997; Annas and Grodin, 1998;
Crouch and Arras, 1998; Glantz et al., 1998; Benatar,
2000; Chang, 2002; Kottow, 2002; Page, 2002; Lo and
Bayer, 2003; Basu et al., 2006; Benatar and Fleischer,
2007) or a fair level of beneﬁts that may but need not
include PTA
3 (Brody, 2002; Orentlicher, 2002;
Participants in the Conference on Ethical Aspects of
Research in Developing Countries, 2002; Lavery, 2004;
Participants in the 2001 conference on ethical aspects of
research in developing countries, 2004; Ballantyne,
2005; Ballantyne, 2006a; Carse and Little, 2008;
Emanuel, 2008; Siegel, 2008).
Reciprocity is the notion that, because one party (X)
beneﬁts another (Y), Y is obliged to beneﬁt X in return.
Reason Mentions classed under reciprocity differed as
to the identity of X (participants or the host commu-
nity) and of Y (the sponsor, researchers, society, the
world,anyhostcountrynon-participantorhostcountry
non-participants who have the same medical condition
as participants). Eight of the 12 possible combinations
of X and Y were mentioned. Some reciprocity Reason
Mentions differed also regarding why participants/com-
munities may be entitled to beneﬁt, e.g. because they
assumed risk (Lie, 2000; Chang, 2002; Macpherson,
2004; Ashcroft, 2005; Merritt, 2007; Carse and Little,
2008; Sachs, 2009; Shah et al., 2009) or were used to
create beneﬁt for mankind (Gostin, 1991).
Role Reason Mentions collectively reﬂected conﬂict-
ing views regarding various role-related obligations,
powers, and limits to the powers of researchers, spon-
sors and governments. For example, many reasons for
the view that PTA need not be ensured appealed to re-
searchers’ or sponsors’ lack of inﬂuence on health policy
or on the drug approval process. A key conﬂict regarded
whether researchers have the same role as doctors
(implying that researchers should ensure PTA) or dif-
ferent role (implying that researchers need not ensure
PTA); reasons appealing to the purpose of research or
to the relationship between researchers and partici-
pants/communities were similarly polarized.
Although logistical obstacles were most often left
unspeciﬁed, a broad range was mentioned. Such obs-
tacleswerealmostwithoutexceptiontakentoimplythat
PTA need not be ensured. Concerns about the safety
and/or efﬁcacy of the trial drug were only used to
argue for the view that PTA need not be ensured in
speciﬁc cases or against the view that PTA should
always be required.
Fourteen non-maleﬁcence Reason Mentions ap-
pealed to the view that participants should not be
worse off after the trial, but completed ‘not be worse
off after the trial than...with respect to...’ differently.
For most such Reason Mentions (11, 76%), participants
should not be worse off than during the trial; for two
(14%), than before it; for one (7%), than if they had not
participated. For most (13, 92%), the relevant respect
was health, whereas for one (7%) it was health care.
Publications endorsing
4 a narrow reason for a con-
clusion agreed about whether the reason was for ensur-
ing PTA or for the view that PTA need not be ensured.
The most frequently endorsed reasons
5 included ones
used just for ensuring PTA (avoid exploiting
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used just to argue that PTA need not be ensured (host
community’s interests may be better served by receiv-
ing beneﬁt other than PTA).
Attitudes Taken to Reasons
Mostreasonswereclearlyacceptedorrejectedatmostor
all Reason Mentions. However, several common
6 broad
reasons were exceptions, including cost (clear attitude
expressed in 20 of 30 Reason Mentions, 66%) and dis-
tributive justice (18 of 23, 78%).
Reasonswererejectedonvariousmoralandempirical
bases. For example, publications mentioning if PTA is
required, this will reduce the incentive to conduct re-
search with consequent loss of potential beneﬁts to
potential research hosts differed as to whether requir-
ing PTA would reduce the research conducted (Cooley,
2001; Nufﬁeld Council on Bioethics Group, 2002;
Macklin, 2004). Those who thought it would disagreed
about whether this was a reason why PTA need not be
ensured. One publication denied this on the grounds
that a reduction in research would not mean a loss of
beneﬁts for communities who would have hosted the
research without receiving its beneﬁts (Glantz et al.,
1998). Another denied it because it is good to prevent
exploitative research (Chang, 2002).
Spectrum and Incidence of Conclusions
Three-quarters of the publications (56, 75%) took a
stance on whether PTA should, or need not, be ensured,
and a quarter (19, 25%) on whether ensuring PTA
should be required (Supplementary Table 1). Of all
the conclusions drawn by publications, the most
common conclusion was that PTA should sometimes
be provided (45 publications, 60%), although some
publications (10, 13%) concluded PTA should always
beprovidedand one(1%)thatthereisno obligation. Of
those concluding PTA should sometimes be provided,
some thought that products/services likely to be beneﬁ-
cial should be provided, but not necessarily PTA to the
trial intervention, e.g. (Participants in the Conference
on Ethical Aspects of Research in Developing Countries,
2002).
Among publications considering whether PTA
should be required (19 publications, 25%), the most
common conclusion was that it should not (16, 84%).
Sixteen (21%)expressed conclusions about pre-trial ob-
ligations to discuss, plan or enter into agreements re-
garding PTA; 13 (17%) endorsed such an obligation.
No publication distinguished these obligations’ scope,
and publications differed about whether such actions
should be required. Six (8%) endorsed an obligation
to advocate for ensuring PTA or to refer participants
to treatment or other trials (Crouch and Arras, 1998;
National Bioethics Advisory Commission Group, 2001;
Nufﬁeld Council on Bioethics Group, 2002, 2005;
Pace et al., 2003; Carse and Little, 2008). Four (5%)
claimed Research Ethics Committees (Institutional
Review Boards) should approve only research with
appropriate PTA arrangements, though without deﬁn-
ing appropriateness.
Nearly half (25, 45%) of publications claiming that
PTA should be provided sometimes or always did not
specify an agent obliged. Publications concluding there
is a PTA-related obligation identiﬁed, collectively and
individually, various agents who have the obligation;
exceptions were obligations to advocate for ensuring
PTA or to refer participants to other care or research,
collectively attributed only to researchers and sponsors,
and to approve research only if it has appropriate PTA
arrangements, attributed only to RECs. It is our opinion
that some but not all publications referencing several
agents claimed that responsible agents should collabor-
ate,butwedidnotsystematicallycollectdataonrespon-
sibilities to collaborate.
Many conclusions that PTA should be provided did
notcontainallofthefollowinginformation:whoshould
fund, provide or receive the trial drug, and/or for how
long.
Reasons Endorsed and Conclusions Drawn by
Individual Publications
Supplementary Table 2 gives, for each publication, the
reasons that were clearly for ensuring PTA or for the
viewthatPTAneednotbeensured,andthatwereclearly
endorsedorrejectedbytheauthor,andthepublication’s
conclusion. Publications varied widely in the number of
narrowreasonsmentioned,includingthosepresentedin
a third party’s voice (range: 1–67) (table available on
request from the corresponding author). The average
number of narrow Types of Reason mentioned by in-
formal philosophy reviews (Glantz et al., 1998; Hutt,
1998; Lie, 2000; National Bioethics Advisory
Commission Group, 2001; Chang, 2002; Nufﬁeld
Council on Bioethics, 2002; Orentlicher, 2002; Page,
2002; Macklin, 2004; Ashcroft, 2005; Grady, 2005;
Ballantyne, 2006a; Carse and Little, 2008; Emanuel,
2008; Lavery, 2008; Zong, 2008; Millum, 2009) was 24,
compared to this review’s 235. The most comprehensive
included publication, an informal review, (Lavery,
174  SOFAER AND STRECH2008) reported 22broadand59narrow Typesof Reason
(58, when narrow types were broadened in the sensitiv-
ity analysis). Among the reasons it did not mention
were, for example, host community’s interests may
be better served by receiving beneﬁt other than PTA.
Use of Relevant Literature
Publications collectively referenced
7 20 regulations,
guidelines or recommendation-containing reports
(instruments), most commonly CIOMS’s guidelines
(12 or 16% of publications mentioned a version of
CIOMS’s guidelines (CIOMS, 1982; CIOMS, 1983;
CIOMS, 1993; CIOMS, 2002)), NBAC’s (National
Bioethics Advisory Commission Group, 2001) (11 or
15% of publications) and NCOB’s reports (Nufﬁeld
Council on Bioethics Group, 2002) (9 or 12% of publi-
cations). Over half of instrument-referencing publica-
tions (28/51, 55%) referenced one or more of these
three. Over two-thirds (14, 67%) of instruments were
referenced by just one publication.
Of the 55 articles included in this systematic review,
the most-referenced articles were the early Glantz et al.
8
(10 publications, 13%), (Cooley, 2001; National
Bioethics Advisory Commission Group, 2001; Nufﬁeld
Council on Bioethics Group, 2002; Orentlicher, 2002;
Page, 2002; Participants in the Conference on Ethical
Aspects of Research in Developing Countries, 2002;
Macklin, 2004; Participants in the 2001 conference on
ethical aspectsof researchindeveloping countries,2004;
Gbadegesin and Wendler, 2006; Emanuel, 2008) and
Crouch and Arras (Crouch and Arras, 1998) (9, 12%)
(Cooley, 2001; Kottow, 2002; Orentlicher, 2002; Page,
2002;Macklin,2004;Ballantyne, 2006b;Gbadegesin and
Wendler, 2006; Emanuel, 2008; Siegel, 2008). Both these
early papers argue that avoiding exploitation requires
ensuring PTA and neither reference any theory of
exploitation or reﬂect on the nature of exploitation.
Many later authors citing these publications accepted
that it was important to avoid exploitation but argued
that this did not require ensuring PTA. These all cited
Wertheimer, whose theory of exploitation implies their
view (Wertheimer, 1999; Wertheimer, 2008); most
reﬂected on the nature of exploitation.
Nearly two-thirds of publications mentioning a reci-
procity reason (13/21, 62%) mentioned just one com-
bination and either did not reference any publication
mentioning a reciprocity reason (7/21, 33%) (Gostin,
1991; Harth and Thong, 1995; Hutt, 1998; Lie, 2000;
Berkley, 2003; Macpherson, 2004; Carse and Little,
2008) or referenced just one (6/21, 29%) (Chang,
2002; Grady, 2005; Ballantyne, 2006b; Zong, 2008;
Sachs,2009;Shahet al.,2009).Fewofthesepublications
(5/21, 24%, 2 of which shared an author) discussed
the formulation and persuasiveness of reciprocity rea-
sons (Cooley, 2001; National Bioethics Advisory
Commission Group, 2001; Merritt and Grady, 2006;
Merritt, 2007; Millum, 2009).
Authors mentioning reasons based on nonmale-
ﬁcence, rights, autonomy or (with few exceptions) the
role of sponsors or researchers, relationships, the pur-
pose of research (Nufﬁeld Council on Bioethics Group,
2002; London, 2005), or distributive justice (Macklin,
2004) failed to acknowledge alternative formulations
of the reason or reﬂect on the reason. None of the
30 cost Reason Mentions distinguished the (very differ-
ent) marginal cost of producing a drug, the cost of
discovery/development and gaining approval, and
this cost combined with that of failed discovery/
development; few distinguished the various cost-
components of PTA such as drug, skilled labor, and
equipment, (e.g. Gbadegesin and Wendler, 2006). Few
publications distinguished the implications of the
reasons they mentioned for PTA for participants in
thetrialversusfornon-participants, (e.g.Millum,2009).
Discussion
Our systematic review found many (36) broad Types of
Reason, based on considerations of morality, legality,
interests and incentives, and/or practicality, for the
views that PTA to the trial drug should, or need not
beensured for participants. It identiﬁed a greater variety
of reasons compared to all publications including infor-
mal philosophy reviews, as conﬁrmed by sensitivity
analysis.
While this systematic review does not settle the ques-
tionofwhetherPTAtothetrialdrugshould,orneednot
be ensured to trial participants, it has various direct and
indirect uses for decision-makers such as policymakers,
regulators, Institutional ReviewBoards (Research Ethics
Committees) and designers of research protocols. Its list
of reasons (Table 1) is the best guard currently available
against failing to identify infrequently published or only
inadequately presented reasons that are nonetheless
strong. On the one hand, if the publishing world is
working well, infrequently published reasons will be
a distraction. On the other hand, the most frequently
published reasons may simply be the best publicized,
perhaps due to conﬂicts of interest that induce authors
to endorse weak reasons and to ignore or reject strong
reasons. In the absence of evidence either way, a
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reasons an equal voice, prior to identiﬁcation of the
strong ones.
Our ﬁnding that the most-endorsed reasons included
ones used just for ensuring PTA and others just for the
view that PTA need not be ensured provides a salutary
warning against considering only reasons that PTA
should be ensured, or only reasons that PTA need not
be ensured. Given the challenges to locating this par-
ticular literature, the list of publications included
(Supplementary Figure 1) obviates the need for
decision-makers to hire hundreds of hours of skilled
labor to locate relevant publications. Furthermore, be-
cause our review describes the search and selection pro-
cess in detail, decision-makers can check that the list is
complete with much less effort than we exerted. Our
summary of positions taken by individual publications
(Supplementary Table 2) may aid decision-makers who
are interested in speciﬁc publications but who cannot
access them or lack the time or analysis skills to extract
the reasons endorsed, attitudes taken to these and con-
clusions drawn.
This systematic review may also aid decision-making
indirectly, by identifying research whose results should
enable better-grounded decisions. Unlike the included
informal reviews, (Glantz et al., 1998; Hutt, 1998; Lie,
2000; National Bioethics Advisory Commission Group,
2001; Chang, 2002; Nufﬁeld Council on Bioethics, 2002;
Orentlicher, 2002; Page, 2002; Macklin, 2004; Ashcroft,
2005; Grady, 2005; Ballantyne, 2006a; Carse and Little,
2008;Emanuel,2008;Lavery,2008;Zong,2008;Millum,
2009) this systematic review identiﬁes all the empirical
or ethical points of dissent. Its identiﬁcation of stark
differences between publications on matters of fact
shows that multi-disciplinary research is urgently
needed to understand the costs,
9 feasibility, legality
and effects of requiring PTA, and any tendency of
PTA offers to potential participants to boost recruit-
ment or to reduce the quality of informed consent.
We consider decision-makers’ need for our systemat-
ic review strong, on the assumptions that the need for a
systematic review increases with the literature’s size, the
variety of ﬁelds or literary genres, the barriers to retriev-
ing and assessing the literature, the differences between
the perspectives of decision-makers and those affected
by their decisions; and the inconsistency and incom-
pleteness of guidance. Admittedly, a systematic review
makes more demands on decision-makers than an in-
formal review, but its advantages justify these demands.
The ﬁrst systematic review of a large reason-based lit-
erature and the ﬁrst of how reasons were used, this
systematic review comprises a starting-point for future
systematic reviews of reasons relevant to decision-
makers.
This systematic review has further implications for
policymaking. It suggests the need to scrutinize key
guidance documents that assume that avoiding exploit-
ation requires ensuring PTA, (CIOMS, 2002) because it
shows that the mature literature rejected the view that
avoiding exploitation requires PTA, e.g. (Brody, 2002;
Orentlicher, 2002; Participants in the Conference on
Ethical Aspects of Research in Developing Countries,
2002; Lavery, 2004; Participants in the 2001 conference
on ethical aspects of research in developing countries,
2004; Ballantyne, 2005; Ballantyne, 2006a; Carse and
Little, 2008; Emanuel, 2008; Siegel, 2008). Moreover,
various ﬁndings suggest that, for practical purposes,
decision-procedures will be needed to set guidelines
on PTA (Daniels, 2008), because authors may fail to
reach agreement: (i) The most-endorsed reasons
included ones used just for ensuring PTA, and others
used just for the view that PTA need not be ensured,
suggesting that disagreement will persist; further discus-
sion is needed, however, to determine if disagreement is
intractable. (ii) Some publications (14, 19%) expressed
no view about any PTA-related obligation. (iii) Like
some prominent instruments, (UNAIDS Group, 2000;
National Bioethics Advisory Commission Group, 2001;
CIOMS, 2002; World Medical Association, 2008;
45CFR46, revised 2009) some publications claiming
PTA should sometimes or always be provided (25,
45%) did not specify an agent obliged.
The systematic review is of interest also to philoso-
phers who seek to understand whether PTA should, or
need not be ensured. First, it reduces the chance that
they, as well as decision-makers, will fail to identify the
strong reasons and their implications for ensuring PTA.
Second, the systematic review aids the identiﬁcation of
reasons relevant to determining whether there are obli-
gations, such as ensuring PTAto trial results (Fernandez
et al., 2003), providing ART to participants who sero-
convert in HIV vaccine trials (Berkley, 2003; Slack et al.,
2005), or providing participants with care for non-trial
conditions
10 (Richardson and Belsky, 2004; Richardson,
2007). Third, its identiﬁcation of inter-publication dif-
ferences in the naming, formulation and implications of
moral reasons suggests that conceptual research is
needed. For example, the differences identiﬁed in au-
thors’ use of terms for concepts such as exploitation and
reciprocity suggests that research is needed on how to
distinguish such concepts. This systematic review
should facilitate this task, in that it presents a list of
very ﬁnely individuated reasons, and so simpliﬁes the
taskintooneofdecidingwhichofthesetomerge.Last,it
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exploitation is justiﬁed or is a serendipitous result of
the focus of much-referenced publications, guidelines
and reports (CIOMS, 1982; CIOMS, 1983; CIOMS,
1991; CIOMS, 1993; Crouch and Arras, 1998; Glantz
et al., 1998; National Bioethics Advisory Commission
Group, 2001; CIOMS, 2002). This focus differs from
that of participants whose views are reported in the
limited empirical literature (Kass and Hyder, 2002;
Shaffer et al., 2006; Sofaer et al., 2009). Such conceptual
research may also inform policy.
Quality
Decision-makers will need a distillation of the best rea-
sons and their implications, and guidance on how to
weight reasons, neither of which this systematic review
provides. There is need for research to construct a suit-
ablemeasureofqualityanddeterminehowbesttodistil.
For the reasons given above, distillation should occur
only after a systematic review such as this one has cap-
tured all the published reasons and how they have been
used. The systematic review remains an essential ingre-
dientofdecision-makers’briefforthereasonsaboveand
because of decision-makers’ need to check the distilla-
tion and its legitimacy.
While we did not collect data on the quality of rea-
sons, our impressions suggest scope for improvement.
A small number of publications seemed excellent e.g.
(Merritt and Grady, 2006; Lavery, 2008). However, the
authors of many interpretations of reasons did not ex-
press awareness of some or any interpretations. Some
reasons were presented unclearly and many were dis-
cussed only brieﬂy or not at all. There has been minimal
or no inﬂuence on the PTA literature of analyses of
social or distributive justice, autonomy or just health
care (Dworkin, 2000; Daniels, 2008) or distinctions in
economics between types of cost. Some publications
appear unaware of theories of exploitation such as
(Wertheimer, 1999; Wertheimer, 2008). The three
most frequently-referenced instruments require PTA
sometimes, (CIOMS, 1982; CIOMS, 1983; CIOMS,
1993; National Bioethics Advisory Commission
Group, 2001; CIOMS, 2002; Nufﬁeld Council on
Bioethics Group, 2002) yet others impose more de-
manding obligations (The European Group on Ethics
in Science and New Technologies to the European
Commission, 2003). Differences in instruments refer-
enced may explain why some (11) legality Reason
Mentions were used for the view that PTA should be
ensured and others (18) for the view that PTA need not
be ensured. While some inter-publication differences
regardingtheinterpretation,implicationsorpersuasive-
ness of exploitation, reciprocity, role and responsive-
ness appeared grounded in awareness of different
interpretations of reasons or their implications, we
cannot rule out that other differences are due to lack
of imagination compounded by ignorance of relevant
literature. We believe that, in general, systematic review
of reasons will improve authors’ awareness of the need
to consider reasons’ alternative interpretations and
implications.
Furthermore, many publications omitted to indicate
the strength of reasons relative to that of other reasons
or to establishing the conclusion in the absence of de-
feating reasons. Some reasoning appeared invalid. For
example, some reasons why PTA need not be ensured
showed, at most, why speciﬁc agents, e.g. sponsors, need
not ensure PTA.
Noincludedpublicationdescribeditssearch,letalone
a reproducible, exhaustive one (McCullough et al.,
2004). Some variation in publications’ number of
narrow reasons mentioned (range: 1–67) was justiﬁed:
one excellent publication scrutinized one reason, expli-
citly stating there may be other reasons it would not
consider (Merritt and Grady, 2006). Yet, other publica-
tions asserted conclusions based on inadequate discus-
sion of fewer reasons than had at the relevant time been
published, e.g. (King, 1997; Brody, 2002; Kottow, 2002;
Basu et al., 2006; Benatar and Fleischer, 2007).
Recommendations
We recommend that authors be aware of a broader
range of relevant literature, including regulations,
guidelines and recommendation-containing reports,
and that they acknowledge when insufﬁcient evidence
limits the strength of factual reasons regarding e.g. cost
(Guyatt et al., 2008). Authors should carefully consider
and state each reason’s implications, if any, for partici-
pants versus non-participants (Millum, 2009) and for
whether it requires PTA in particular or, rather, a pack-
age of possible beneﬁts that need not include PTA,
(Participants in the 2001 conference on ethical aspects
of research in developing countries, 2004) and also any
all-things considered conclusion. Further research
should address which inter-publication differences are
legitimate. As existing comparative legal analyses are of
small samples of instruments, (Nufﬁeld Council on
Bioethics Group, 1999; National Bioethics
Advisory Commission Group, 2001; Macklin, 2004;
Lavery, 2008; Zong, 2008) we recommend the
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from a book-length, interdisciplinary discussion.
Implementing these recommendations may increase
inter-publication agreement and improve PTA policy.
Limitations
We did not assess quality because the methodology of
quality assessment poses substantial challenges and has
yet to be developed. However, in order to answer our
secondary research question on how reasons have been
used, we did collect data on whether Reason Mentions
referenced appropriately. Unfortunately, such data is
inadequate even as a partial indicator of quality: pos-
sibly, lack of an appropriate reference is in some genres
not an indicator of low quality, as our ﬁnding that some
informal reviews written by prominent authors give few
or no references (Ashcroft, 2005) may suggest.
Furthermore, it was conceptually and practically difﬁ-
cult to decide when a reason was original (and thus to
conclude that no reference was necessary) and, in some
cases, also to decide when a reference was appropriate.
The data nonetheless gave some indication of authors’
breadth of awareness of relevant literature and
guidelines.
A further limitation of this systematic review is that it
may fail to capture the perspectives of participants, in-
dustry, regulators and some lawyers: our particular in-
clusion conditions were not met by empirical literature
reporting participants’ views, industry grey literature,
laws, guidelines, cases or commentaries. Nonetheless,
some of their reasons were captured vicariously through
publications’ attribution of reasons to other parties or
when publications reasoned e.g. that PTA should be
provided because guidelines so require. Our systematic
review also gives some indication of instruments’ inﬂu-
ence on the literature.
We may have missed some qualifying publications.
Databases’ index terms did not include post-trial access
or synonym, and were applied inconsistently. Although
we searched for and within books on research ethics, we
did not search systematically for these. Databases did
not provide abstracts for some publications, which we
screened based on title and keywords alone. Although
we did not exclude publications based on language, our
database selection created bias in favor of
English-language publications and this may explain
why all the publications included were written in
English. Wecontacted some, butnot all authors of qual-
ifying publications for help in identifying others.
Neither author was blinded as to publications’ identity:
one (N.S.) knew much literature too well to be blinded.
Selection of publications was consensus-based; possibly,
independent scoring, or coding by others, might select
different publications (McCullough et al., 2007). Our
operational deﬁnition of informal philosophy review
did not capture some publications that seemed to be
informal philosophy reviews. However, an operational
deﬁnition was necessary; ours was justiﬁed (the opera-
tional deﬁnition and justiﬁcation are available on
request from the corresponding author); and we rest
our ﬁnding about the relative comprehensiveness of
our systematic review on the maximum number of rea-
sons mentioned by any publication, as calculated in the
sensitivity analysis, not on the average number of rea-
sons given by informal philosophy reviews.
There were also limitations to our assignment of
Reason Mentions to Reason Types. (1) Because we
decided to assign Reason Mentions to Reason Types
based not just on the words used to express the reasons,
but also on the meaning of those words, it is possible
that different reviewers would make different assign-
ments. Our analysis is nonetheless valid because review-
ers assigned types independently, checked for
discrepancies, and were able to resolve all discrepancies.
(2) Differences in referencing conventions and with es-
tablishing originality made it difﬁcult to decide when an
appropriate reference was (not) given where one was
necessary.
Our sum of Types of Reasons had additional limita-
tions. (1) Types could be made narrower or broader;
some broad types cover diverse narrow types; and
there may be similarly good reasons to class a narrow
TypeofReasonunderdifferentbroadtypes.Inresponse:
(i) our sensitivity analysis shows that our systematic
review mentions a much greater variety of reasons
than any publication included, whether Types of
Reason are individuated narrowly or broadly.
(ii) Narrowly-individuated narrow Types of Reason
are meaningful and homogenous and their assignment
tobroadtypeswasobviousandwell-justiﬁed.(iii)When
deciding how broad the broad Types of Reason should
be, we faced a trade-off between having few but hetero-
geneous broad types versus impractically many, but
more natural broad types. Given the practical aims of
this article, we allowed some heterogeneity. (2) We
summed the number of Reason Mentions that were
used to support slightly different types of conclusions.
However, we gave qualitative results where more appro-
priate. Wenotealsothatclassicalsystematicreviews face
the analogous problem that the studies reviewed ad-
dressed slightly different research questions. (3) We
did not exclude, from the sum of Reason Mentions,
178  SOFAER AND STRECHreasons mentioned by the same author in different
included publications. However, removal of such re-
peated reasons would make little difference to the
sum. (4) The difference between the number of
narrow Types of Reason identiﬁed by our systematic
review and the most comprehensive informal review is
slightly exaggerated because our systematic review used
some narrow types such as unspeciﬁed logistical obs-
tacles. However, there were only 12 unspeciﬁed types
(0.5% of the narrow Types of Reason).
This systematic review presented data on the fre-
quency with which Types of Reason were mentioned
in order to identify reasons on which attention has
focused, and neglected reasons. However, this data
should be presented with caution. Research is needed
to determine if decision-makers assume that the more
common reasons are the stronger ones; if so, authors of
future systematic reviews targeted at decision-makers
should consider not presenting data on how frequently
(or infrequently) reasons are mentioned.
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Notes
1. The terms are listed in a table available from the
corresponding author.
2. In this sentence as elsewhere, counts of reasons ex-
clude repeats of reasons in the same publication.
3. Publications agreeing, that a fair level of beneﬁts
may but need not include PTA, with the latter
view were on average more recent.
4. Sometimes or always.
5. Endorsed >10 times and endorsed by >95% of
commentators that mentioned the reason.
6. >22 Reason Mentions.
7. References were counted only if they were references
given when mentioning reasons why PTA should, or
need not be ensured.
8. Publications that referenced Glantz et al., but not
when mentioning a qualifying reason, are excluded
from this count.
9. This will require the identiﬁcation an appropriate,
measurable concept of cost, as well as empirical
research.
10. A result tangential to this article is that, for the
above reasons, systematic reviews may be an im-
portant research tool for philosophical bioethicists.
However, systematic reviews of philosophical litera-
ture pose various conceptual and methodological
challenges (McCullough et al., 2007) (see also
p. [complete once paper has been type-set]).
11. The issue of whether to include frequency data
is discussed in greater length in (Sofaer and
Strech, 2011; Strech and Sofaer, How to write a sys-
tematic review of reasons, manuscript.)
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Table A1. Search terms and strings
Database Search string
Medline Focus on ethics:
(("Ethics"[Mesh] OR "Human Rights"[Mesh] OR "ethics"[Subheading])) AND
((((((((((((("Health Services Accessibility"[Mesh])) OR (("Continuity of Patient
Care"[Mesh]))) OR (("Drugs, Investigational/supply and distribution"[Mesh]))) OR
((post-trial provision))) OR ((post-trial obligations))) OR ((post-trial access))) OR
((post-trial beneﬁts))) OR ((post-trial responsibility))) OR ((follow-up)))) AND
((((("Clinical Trials as Topic"[Mesh])) OR (("Biomedical research"[Mesh]))) OR
(("Human experimentation"[Mesh]))))))
Focus on developing countries:
((((("Vulnerable Populations"[MeSH Terms])) OR (("Developing
Countries"[Mesh])))) AND (((("Patient Advocacy"[MeSH Terms])) OR
(("Ethics"[Mesh] OR "Human Rights"[Mesh] OR "ethics"[Subheading]))))) AND
(((((((("clinical trials as topic"[Mesh])) OR (("Human Experimentation"[Mesh])))
OR (("Biomedical Research"[MeSH Terms]))) OR (("Drugs, Investigational/supply
and distribution"[Mesh])))) OR (("Research/organization and
administration"[Mesh]))))
Disjunction of terms used to refer to PTA in included publications:
a
“post-trial provision” or “post-trial obligation” or “post-trial obligations” or
“post-trial access” or “posttrial access” or “post-trial beneﬁt” or “post-trial beneﬁts”
or “post-trial responsibility” or “post-trial responsibilities” or “prior agreements”
Westlaw “post-trial access”
JSTOR “post-trial obligation”
Scidev.net “post-trial responsibility”
LocatorPlus “post-trial obligations”
Euroethics “reasonable availability”
“post-trial provision”
“Post-trial follow-up”
“after the trial" and research and drug
ETHXweb post-trial
Ethos-Beta
Electronic Theses
Online Service
post-trial (any ﬁeld) and (ethics (any ﬁeld) or bioethics (any ﬁeld))
WorldCat Dissertations “post-trial access” (keyword)
“after research” (keyword)
“post-trial” (keyword)
exploitation and “clinical research”
aThese terms also included post-trial followup, after participation or aftercare, but we excluded them from the search string
because the resulting searches were insufﬁciently speciﬁc.
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